EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience

Wei Yee Chan iD, Hannah Al-Yousuf iD, Ho Pui Jeff Lam, Sarah Leong iD, Jiexin Zheng, Richard Burt iD, Andrew J Wilson, Ke Xu iD, Kate Stringaris, Samah Alimam iD, Kavita Raj iD, Rajeev Gupta und 8 weitere

British Journal of Haematology · 2026

DOI: 10.1111/bjh.70676 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2026. Verfasst von Wei Yee Chan und 19 weiteren Autor:innen. Beteiligte Einrichtung: University College London Hospitals, NHS Foundation Trust, London, UK. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, fms-Like Tyrosine Kinase 3, Antineoplastic Combined Chemotherapy Protocols, Mutation. Die Arbeit nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In FMS-like tyrosine kinase 3 (FLT3)-mutated relapsed/refractory acute myeloid leukaemia, gilteritinib, azacitidine and venetoclax is an effective salvage option with an ORR of 100% (mCRc [MLFS + CRc] 93%). Sixty-two per cent of patients treated with intention-to-transplant proceeded to allogeneic haematopoietic stem cell transplant, of whom 50% remain in long-term remission (median follow-up 43 months).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, Acutefms-Like Tyrosine Kinase 3Antineoplastic Combined Chemotherapy ProtocolsMutationHumansSulfonamidesBridged Bicyclo Compounds, HeterocyclicAniline CompoundsAzacitidinePyrazinesMiddle AgedFemaleAgedUnited KingdomRecurrenceTreatment Outcome

Stichwörter der Autor:innen

AMLFLT3gilteritinibreal‐worldvenetoclax

Substanzen

SulfonamidesBridged Bicyclo Compounds, HeterocyclicvenetoclaxAniline CompoundsgilteritinibAzacitidinePyrazinesfms-Like Tyrosine Kinase 3FLT3 protein, human

Autor:innen und Institutionen

  • University College London Hospitals, NHS Foundation Trust, London, UK.
  • University College London, London, UK.
  • GOS Institute of Child Health, UCL, London, UK.

ORCID-Profile: Wei Yee Chan, Hannah Al-Yousuf, Sarah Leong, Richard Burt, Ke Xu, Samah Alimam, Kavita Raj, Anish Tailor, Elspeth M Payne

Zitieren

APA

Chan, W. Y., Al-Yousuf, H., Lam, H. P. J., Leong, S., Zheng, J., Burt, R., Wilson, A. J., Xu, K., Stringaris, K., Alimam, S., Raj, K., Gupta, R., Kottaridis, P., Tailor, A., Burgoyne, R., Mansour, M. R., Khwaja, A., Sellar, R., Payne, E. M., & O'Nions, J. (2026). Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience. British Journal of Haematology. https://doi.org/10.1111/bjh.70676

Vancouver

Chan WY, Al-Yousuf H, Lam HPJ, Leong S, Zheng J, Burt R, et al. Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience. British Journal of Haematology. 2026. doi:10.1111/bjh.70676

BibTeX
@article{Chan2026,
  author = {Chan, Wei Yee and Al-Yousuf, Hannah and Lam, Ho Pui Jeff and Leong, Sarah and Zheng, Jiexin and Burt, Richard and Wilson, Andrew J and Xu, Ke and Stringaris, Kate and Alimam, Samah and Raj, Kavita and Gupta, Rajeev and Kottaridis, Panagiotis and Tailor, Anish and Burgoyne, Rebecca and Mansour, Marc R and Khwaja, Asim and Sellar, Rob and Payne, Elspeth M and O'Nions, Jenny},
  title = {Real‐world outcomes of triplet therapy with gilteritinib, azacitidine and venetoclax in FMS‐like tyrosine kinase 3 ( FLT3 )‐mutated relapsed/refractory acute myeloid leukaemia: A UK single‐centre experience},
  journal = {British Journal of Haematology},
  year = {2026},
  doi = {10.1111/bjh.70676}
}
Kostenlos starten →